Journal of endodontics · 2026
Injectable and retrievable calcium salicylate hydrogel promotes sustained periapical bone regeneration in a beagle dog model of apical periodontitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aguilar Perez Fernando Javier, Mahmoud Abdel H, Cui Muyun, Hasegawa Karin, Tripti Nabila Jaman, Ren Brenna, Luo Huiting, Fu Shi, Sloutski Aaron, Zaliznyak Tatiana, Sadasivan Chander, Manders Thomas, Deng Yuefan, Walker Stephen, Simon Marcia, Cymerman Jerome J, Rafailovich Miriam
Аннотация
INTRODUCTION: Persistent apical periodontitis remains a clinical challenge requiring both effective disinfection and bone regeneration. This study tested the hypothesis that an injectable, retrievable F127-DMA/CASA hydrogel facilitates periapical bone healing by combining antimicrobial action with osteogenic induction.
METHODS: Periapical lesions were induced in 18 single-rooted teeth of two beagle dogs. After the periapical lesions were confirmed, teeth were randomly assigned to three groups: F127-DMA/CASA, Ca(OH)2, or an untreated control. For the CASA and Ca(OH)2groups, intracanal medicaments were placed and then removed after 4 weeks; in the control group, the root canals were left without medicament. Periapical lesion volumes were tracked via cone-beam computed tomography and 3D volumetric analysis for up to 10 weeks post-medication. In vitro, human osteoblasts were exposed to the hydrogel to evaluate osteogenic marker expression by RT-qPCR and to characterize mineral deposition by spectroscopic analysis and electron microscopy.
RESULTS: The F127-DMA/CASA group achieved the highest overall mean lesion volume reduction (54%) and significantly outperformed both control (26%) and Ca(OH)2 treatment (38%) at 10-weeks (p<0.03). Healing progressed at three different rates. The fastest occurred at 0-2 weeks, corresponding to initial cleaning of the canal, where Ca(OH)2 and CASA were similar to each other and only moderately faster than control. The Ca(OH)2 and control reached a plateau after two weeks, with only a small subsequent increase (10% and 6%, respectively) at week 10. In contrast, CASA continued to show a significantly higher rate (20%) between weeks 2 and 6, which slowed (6%) between weeks 6 and 10, but remained higher than Ca(OH)2 and control. A surprising result was the observation of new bone formation in two of the CASA-treated teeth. These results were further supported by auxiliary in vitro experiments in which osteoblasts exposed to CASA showed a 3- to 25-fold increase in mRNA levels of all targeted osteogenic markers and robust bone like mineral deposition.
CONCLUSIONS: The F127-DMA/CASA hydrogel achieved superior, sustained periapical healing and demonstrated bone regeneration as compared with conventional medicaments in a clinically relevant animal model. These outcomes were supported in vitro, exposing the molecular upregulation of osteoblast maturation markers and deposition of bone analog minerals, suggesting the system functions as a bioactive regenerative therapy beyond traditional disinfection.
METHODS: Periapical lesions were induced in 18 single-rooted teeth of two beagle dogs. After the periapical lesions were confirmed, teeth were randomly assigned to three groups: F127-DMA/CASA, Ca(OH)2, or an untreated control. For the CASA and Ca(OH)2groups, intracanal medicaments were placed and then removed after 4 weeks; in the control group, the root canals were left without medicament. Periapical lesion volumes were tracked via cone-beam computed tomography and 3D volumetric analysis for up to 10 weeks post-medication. In vitro, human osteoblasts were exposed to the hydrogel to evaluate osteogenic marker expression by RT-qPCR and to characterize mineral deposition by spectroscopic analysis and electron microscopy.
RESULTS: The F127-DMA/CASA group achieved the highest overall mean lesion volume reduction (54%) and significantly outperformed both control (26%) and Ca(OH)2 treatment (38%) at 10-weeks (p<0.03). Healing progressed at three different rates. The fastest occurred at 0-2 weeks, corresponding to initial cleaning of the canal, where Ca(OH)2 and CASA were similar to each other and only moderately faster than control. The Ca(OH)2 and control reached a plateau after two weeks, with only a small subsequent increase (10% and 6%, respectively) at week 10. In contrast, CASA continued to show a significantly higher rate (20%) between weeks 2 and 6, which slowed (6%) between weeks 6 and 10, but remained higher than Ca(OH)2 and control. A surprising result was the observation of new bone formation in two of the CASA-treated teeth. These results were further supported by auxiliary in vitro experiments in which osteoblasts exposed to CASA showed a 3- to 25-fold increase in mRNA levels of all targeted osteogenic markers and robust bone like mineral deposition.
CONCLUSIONS: The F127-DMA/CASA hydrogel achieved superior, sustained periapical healing and demonstrated bone regeneration as compared with conventional medicaments in a clinically relevant animal model. These outcomes were supported in vitro, exposing the molecular upregulation of osteoblast maturation markers and deposition of bone analog minerals, suggesting the system functions as a bioactive regenerative therapy beyond traditional disinfection.